Orexo
19,26
SEK
-0,1 %
ORX
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Vær den første som følger denne virksomhed
-0,1%
+104,89%
+38,36%
-8,29%
+24,58%
+14,78%
-47,09%
-68,94%
-78,59%
Orexo is a Swedish pharmaceutical company that develops medicines based on proprietary formulation technologies that meet major medical needs. In the US market, Orexo offers treatment solutions for patients suffering from opioid addiction and related diseases. Products targeting other therapeutic areas are developed and commercialized worldwide in collaboration with partners. The head office, where the research and development work is conducted, is located in Uppsala.
Læs mereMarkedsværdi
668,53 mio. SEK
Aktieomsætning
1,37 mio. SEK
Omsætning
638,8 mio.
EBIT %
-17,14 %
P/E
-
Udbytteafkast, %
-
Finanskalender
6.2
2025
Årsrapport '24
6.5
2025
Delårsrapport Q1'25
16.7
2025
Delårsrapport Q2'25
ViserAlle indholdstyper
Orexo enters into collaboration with Abera to develop nasal powder vaccines based on the AmorphOX technology
Carnegie Commissioned Research: Orexo: A less cloudy day dawns as a settlement is struck
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools